03-05-2023 : 769 Pharmacists work as Medical Representative, of which 39 work as Senior Medical Representative * 02-06-2020 : 216 non Pharmacists work as Medical Representative, and 54 work as Senior Medical Representative * 05-06-2023 : In Lebanon, 88 generic medicinal products are more expensive than their Originators * 31-12-2019 : A medicinal product refused in Europe is marketed in Lebanon * 05-06-2023 : At least 332 medicinal products are available on the Lebanese market and are not available in the country of origin * 05-06-2023 : The price of the most expensive medicine available in Lebanon is 30434557 LL * 05-06-2023 : At least 1309 medicinal products are more expensive in Lebanon than in the countries of origin * 01-01-2019 : Daktavira, a generic of Daklinza, is registered in Lebanon but has no public price * 31-12-2019 : 352 medicinal products have been declared as non-marketed or withdrawn * 09-11-2021 : 64.72% of lebanese pharmacists are female * 31-12-2019 : 486 medicines were submitted to the Ministry of Health for a marketing authorization, and 514 medicines were registered to date * 15-06-2018 : The Minister of Public Health, has decided to suspend the commercialization of AB Slim (Ab Care Medical Herbs), which contains sibutramine, sildenafil and phenolphthalein * 01-06-2020 : Some Non-Marketed medicines are still imported * 01-06-2020 : Ixempra, a medicinal product withdrawn in Europe is imported to lebanon * 01-06-2020 : A vaccine made in India, removed from WHO list of prequalified vaccines, is submitted for registration in Lebanon * 01-06-2020 : Lebanon has 14 CROs, and is ranked as one of the largest countries in the world in clinical studies. According to the WHO, 817 clinical studies are currently conducted in Lebanon. * 05-01-2021 : * 01-10-2023 : Adakveo is now withdrawn from use in the European Union due to lack of therapeutic efficacy *
PMS-Fingolimod : | |
Type | Medicine Authorised |
Originator | Gilenya |
Agent | UPO |
Distributor | UPO |
Laboratory | Pharmascience |
Responsible Party | Pharmascience Inc |
Origin | Canada |
Manufacturer | Pharmascience Inc |
Manufacturing Type | G |
Origin | Canada |
ATC | L04AA27 |
PMS-Fingolimod :
PMS-Fingolimod :
PMS-Fingolimod :
PMS-Fingolimod :
PMS-Fingolimod :
Hazard Level |
---|
◼ Major |
◼ Moderate |
◼ Minor |
◼ Safe |
PMS-Fingolimod :
Frequency | Percentage |
---|---|
Very Common | ≥ 1/10 |
Common | ≥ 1/100 - < 1/10 |
Uncommon | ≥ 1/1,000 - < 1/100 |
Rare | ≥ 1/10,000 - < 1/1,000 |
Very Rare | < 1/10,000 |
Unknown | Cannot be Estimated |
Effect | Frequency |
---|---|
Acute disseminated encephalomyelitis | Not known |
Alopecia | Common |
ALT increased | Very Common |
AST increased | Very Common |
Asthenia | Common |
Atrioventricular block (AVB) | Common |
B-cell lymphoma | Not known |
Back pain | Very Common |
Blood triglycerides increased | Common |
Bradyarrhythmia | Not known |
Bradycardia | Common |
Bronchitis | Common |
Carbon monoxide diffusing capacity decreased | Not known |
Cardiac arrest | Not known |
Cough | Very Common |
Cryptococcosis | Not known |
Death | Not known |
Depressed mood | Uncommon |
Depression | Common |
Diarrhoea (Diarrhea) | Very Common |
Dizziness | Common |
Dyspnoea (dyspnea) | Common |
Eczema | Common |
Epstein-Barr virus associated lymphoma | Not known |
Forced expiratory volume decreased | Not known |
Gamma-GT increased | Very Common |
Haemorrhagic stroke | Not known |
Headache | Very Common |
Hepatic enzyme increased | Very Common |
Herpes virus infection | Common |
Histiocytosis haematophagic | Not known |
Hypersensitivity | Not known |
Hypertension | Common |
Infection | Not known |
Influenza-like illness | Very Common |
Ischaemic stroke | Not known |
Leucopenia (Leukopenia) | Common |
Lower respiratory tract infection | Common |
Lymphoma | Not known |
Lymphopenia | Common |
Macular oedema | Uncommon |
Meningitis cryptococcal | Not known |
Migraine | Common |
Neutrophil count decreased | Uncommon |
Peripheral arterial occlusive disease | Not known |
Pneumonia | Uncommon |
Posterior reversible leukoencephalopathy syndrome (PRES) | Rare |
Pruritus | Common |
Sinusitis | Very Common |
Skin rash | Not known |
T-cell lymphoma | Not known |
Tinea infection | Common |
Tinea versicolour | Common |
Vision blurred | Common |
Visual acuity reduced | Not known |
PMS-Fingolimod :
▲ Most Expensive |
▼ Least Expensive |
P.P. = | Public Price |
P/U = | Price Per Unit |
- Products with same active ingredients |
- Products with same strength |
- Products with same route of administration |
NB : Products With Same Indication |
Different Units By MoH Code
PMS-Fingolimod MoH 10373 :
Form | Capsule |
Package Size | Box of 28 |
Strength | 0.5mg |
Storage Condition | 15-30°C Away from moisture |
Public Price | 1615915 L.L. |
Stratum | E2 |
NSSF | ✘ |
Quarantine | ✘ |
Reg. Number | 25020/1 |
Submission date | 25/02/2020 |
Registration Year | 02/10/2020 |
Pending Year | 02/10/2020 |
Price Comparison
● Country: | Lebanon | |
● Form: | Capsule | |
● Package Size: | Box of 28 | |
● Public Price: | 1615915 LBP | ( 1,615,915.00 LBP ) |
● Pack size unit used: | 28 | |
● Cost/Unit: | 57711,25 LBP | ( 57,711.00 LBP ) |
● Pricing Date: | 13/06/2024 |
You have to register to view this info
Drop File